Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus endocrine therapy versus paclitaxel in aggressive HR-positive/HER2-negative advanced breast cancer
2020-001648-24Phase 2Active
- Sponsor
- MEDSIR
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib, letrozole, fulvestrant and paclitaxel in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoint: 12-week overall response rate. Started Jun 2021; status: active.
02
Drugs
abemaciclibletrozolefulvestrantpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-001648-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001648-24.